Skip to main content

Research Repository

Advanced Search

All Outputs (8)

Asthma phenotypes: Do cough and wheeze predict exacerbations in persistent asthma? (2017)
Journal Article
Morjaria, J. B., Rigby, A. S., & Morice, A. H. (2017). Asthma phenotypes: Do cough and wheeze predict exacerbations in persistent asthma?. European respiratory journal, 50(6), Article 1701366. https://doi.org/10.1183/13993003.01366-2017

Copyright © ERS 2017. Little is known of the long-term symptom profile in uncontrolled asthma and whether symptoms can predict distinct phenotypes. The primary objective of these analyses was to assess diurnal profile of cough and wheeze in an uncont... Read More about Asthma phenotypes: Do cough and wheeze predict exacerbations in persistent asthma?.

Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - A randomised controlled study (2017)
Journal Article
Sathyapalan, T., Aye, M., Rigby, A. S., Fraser, W. D., Kilpatrick, E. S., & Atkin, S. L. (2017). Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - A randomised controlled study. Scientific reports, 7(1), Article ARTN 15366. https://doi.org/10.1038/s41598-017-15402-9

© 2017 The Author(s). Type 2 diabetes (T2DM) is associated with increased risk of fractures. Soy supplementation has been shown to have a beneficial effect on bone turnover markers (BTM) in postmenopausal women. However, the effect of soy supplementa... Read More about Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - A randomised controlled study.

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials (2017)
Journal Article
Cleland, J. G., Bunting, K. V., Flather, M., Altman, D. G., Holmes, J., Coats, A. J., …Beta-blockers in Heart Failure Collaborative Group. (2018). Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials. European Heart Journal, 39(1), 26-35. https://doi.org/10.1093/eurheartj/ehx564

Aims: Recent guidelines recommend that patients with heart failure and left ventricular ejection fraction (LVEF) 40-49% should be managed similar to LVEF ≥50%. We investigated the effect of beta-blockers according to LVEF in double-blind, randomised,... Read More about Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials.

Deoxynivalenol biomarkers in the urine of UK vegetarians (2017)
Journal Article
Wells, L., Hardie, L., Williams, C., White, K., Liu, Y., De Santis, B., …Sathyapalan, T. (2017). Deoxynivalenol biomarkers in the urine of UK vegetarians. Toxins, 9(7), 196. https://doi.org/10.3390/toxins9070196

Deoxynivalenol (DON) is produced by Fusarium graminearum and is one of the most commonly occurring trichothecenes. Vegetarians are alleged to be a high-risk group for DON exposure due to high intakes of cereals susceptible to the growth of the mycoto... Read More about Deoxynivalenol biomarkers in the urine of UK vegetarians.

Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure (2017)
Journal Article
Kotecha, D., Flather, M. D., Altman, D. G., Holmes, J., Rosano, G., Wikstrand, J., …Cleland, J. G. (2017). Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. Journal of the American College of Cardiology, 69(24), 2885-2896. https://doi.org/10.1016/j.jacc.2017.04.001

Background The relationship between mortality and heart rate remains unclear for patients with heart failure with reduced ejection fraction in either sinus rhythm or atrial fibrillation (AF). Objectives This analysis explored the prognostic importan... Read More about Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure.

Soy protein improves cardiovascular risk in subclinical hypothyroidism : a randomized double-blinded crossover study (2017)
Journal Article
Sathyapalan, T., Javed, Z., Rigby, A. S., Kilpatrick, E. S., & Atkin, S. L. (2017). Soy protein improves cardiovascular risk in subclinical hypothyroidism : a randomized double-blinded crossover study. Journal of the Endocrine Society, 1(5), 423-430. https://doi.org/10.1210/js.2016-1068

© 2017 Endocrine Society. Background: Soy protein with isoflavones appears to have an adverse effect on thyroid function, but it is not known whether it is the protein or isoflavone component that is deleterious. The effect of isoflavone-free soy on... Read More about Soy protein improves cardiovascular risk in subclinical hypothyroidism : a randomized double-blinded crossover study.

Pseudotumor cerebri syndrome in childhood : incidence, clinical profile and risk factors in a national prospective population-based cohort study (2017)
Journal Article
Matthews, Y., Dean, F., Lim, M. J., Mclachlan, K., Rigby, A. S., Solanki, G. A., …Kennedy, C. R. (2017). Pseudotumor cerebri syndrome in childhood : incidence, clinical profile and risk factors in a national prospective population-based cohort study. Archives of Disease in Childhood, 102(8), 715-721. https://doi.org/10.1136/archdischild-2016-312238

Aim To investigate the epidemiology, clinical profile and risk factors of pseudotumor cerebri syndrome (PTCS) in children aged 1-16 years. Methods A national prospective population-based cohort study over 25 months. Newly diagnosed PTCS cases notifie... Read More about Pseudotumor cerebri syndrome in childhood : incidence, clinical profile and risk factors in a national prospective population-based cohort study.

Inhaled corticosteriod use and the risk of pneumonia and COPD exacerbations in the UPLIFT study (2017)
Journal Article
Morjaria, J. B., Morice, A. H., Morice, A., Rigby, A., & Morjaria, J. (2017). Inhaled corticosteriod use and the risk of pneumonia and COPD exacerbations in the UPLIFT study. Lung, 195(3), 281-288. https://doi.org/10.1007/s00408-017-9990-8

Rationale Unlike many other COPD studies, the 4-year UPLIFT trial permitted inhaled corticosteroid (ICS) use during run-in and treatment phases. This provided the opportunity to prospectively observe the continuing effects of ICS on respiratory event... Read More about Inhaled corticosteriod use and the risk of pneumonia and COPD exacerbations in the UPLIFT study.